Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the ppar-α/γ agonist aleglitazar

HIGHLIGHTS

• who: Esmu00e9e J. Grobbee et al. from the University School of Medicine, UNITED STATES Erasmus MC Medical Center, Rotterdam, The Netherlands have published the research work: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-u03b1/u03b3 agonist aleglitazar, in the Journal: PLOS ONE of 15/07/2022
• what: This study reported a higher rate of improvement of liver histology compared to placebo (34% vs. 19%), although this difference did not reach . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.